69 results
8-K
EX-99.1
IVVD
Invivyd Inc
9 Feb 24
Index to Consolidated Financial Statements
4:01pm
(In thousands, except share and per share amounts)
Year Ended December 31,
Operating expenses:
Research and development(1)
Acquired in-process research … into a lease for dedicated laboratory and office space in Newton, MA for research and development purposes. The Company performs research and development
8-K
EX-99.1
962jxaelall 1vf
30 Mar 22
Results of Operations and Financial Condition
7:40am
8-K
EX-99.1
re3n1df7ryvds
10 Nov 22
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
4:13pm
8-K
EX-99.1
w9q10z6wo a4
15 Aug 22
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
7:22am
10-Q
kc2u0d8l6sp5g uijz
20 Sep 21
Quarterly report
4:17pm
8-K
EX-99.1
awt9bx5oa3a
13 May 22
Adagio Therapeutics Reports First Quarter 2022 Financial Results
7:00am
10-K
c85g3p2
31 Mar 22
Annual report
8:18am
8-K
EX-99.1
22mu47ut zdywq1ngy61
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
EX-99.1
uw7 qa5f2dsrjrqd5of
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
S-1/A
mdgob
2 Aug 21
IPO registration (amended)
6:20am
S-1
3q40qs05 ftq
16 Jul 21
IPO registration
4:56pm